Extracellular vesicles for the treatment of preeclampsia
Extracellular vesicles for the treatment of preeclampsia
复制标题
DOI：
10.1016/j.tice.2022.101860
复制
发表时间：
2022
期刊：
影响因子：
--
通讯作者：
Jia Ruizhe
中科院分区：
文献类型：
--
作者：
Yu Zhaoer;Gao Mingming;Zhang Wei;Yao Dan;Qian Yating;Jia Ruizhe
Preeclampsia is a common pregnancy complication, characterized by hypertension, proteinuria, or other organ or system lesions that appear after 20 weeks of gestation. Preeclampsia, a systemic multisystem disease of placental origin, is also one of the leading causes of maternal mortality. Serious complications such as HELLP syndrome and placental abruption that occur in patients with preeclampsia without active treatment will be life threatening. In recent years, extracellular vesicles, especially those derived from mesenchymal stem cells, have been widely used in the treatment of various diseases due to their excellent anti-inflammatory, tissue regeneration-promoting, and immunomodulatory properties. In this review, we attempt to summarize recent advances in the use of different sources of extracellular vesicles for the treatment of preeclampsia, and also describe the biological pathways and molecules involved in each study. Extracellular vesicle therapy has a good repair effect on trophoblast and endothelial system, and is a promising treatment for preeclampsia. • Extracellular vesicle therapy has emerged as a promising approach for the treatment of preeclampsia. • Extracellular vesicles can repair damaged placental trophoblast cells and vascular endothelial cells. • The therapeutic effect of extracellular vesicles has been mainly attributed to their pro-angiogenic properties. • Engineered extracellular vesicles may have better therapeutic effects.
